FreeBioList

Catalysts / OCUL

Ocular Therapeutix (OCUL) catalysts

Upcoming FDA decisions and readouts we track for Ocular Therapeutix, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 2 Rows last checked — 11 Sep 2026

FreeBioList tracks 2 upcoming catalysts for Ocular Therapeutix (OCUL, listed on Nasdaq). Both concern AXPAXLI (OTX-TKI) (Wet age-related macular degeneration).

First on the list: the Phase 3 readout for AXPAXLI (OTX-TKI) (Wet age-related macular degeneration), guided by the company to Q4 2026. By stage, the upcoming rows are 2 Phase 3 readouts.

Both rows link to SEC filings (8-K or 6-K). Both have been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.

Background reading: How to read a Phase 3 topline readout.

Ticker
OCUL
Next catalyst
Q4 2026
Type
Phase 3 readout
Listed options
Yes
Company ▾ Drug ▾ Effect / indication Next catalyst ▾ Phase / type ▾ Status ▾ Source Options
Ocular Therapeutix OCUL · Nasdaq AXPAXLI (OTX-TKI) Wet age-related macular degeneration Q4 2026
company guidance		 Phase 3 readout Verified 8-K exhibit 99.1 ↗ Yes
Ocular Therapeutix OCUL · Nasdaq AXPAXLI (OTX-TKI) Wet age-related macular degeneration Q1 2028
company guidance		 Phase 3 readout Verified 8-K exhibit 99.1 ↗ Yes

Companies working on related conditions

Also due in Q4 2026